Streetbeat News

Stock Prices

SWKH

SWK Holdings (NASDAQ:SWKH) reported Q3 earnings of $0.38 per share, beating the analyst consensus estimate of $0.34 by 11.76%. However, this is a 40.63% decrease from the same period last year. The company's quarterly sales were $8.96 million, missing the analyst consensus estimate of $9.30 million by 3.63%, and marking a 34.17% decrease from the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 09, 2023 | 12:35 pm

FREE

Whole Earth Brands has revised its FY2023 sales guidance downwards from $550M-$565M to $540M-$550M, which is below the estimated $552.78M. However, the company has increased its adjusted EBITDA from $76M-$78M to $77M-$79M and reduced its capital expenditures from $9M to $8M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:34 pm

MTSI

MACOM Technology Solutions Holdings (MTSI) has projected its Q1 revenue to be between $149M-$153M, lower than the estimated $155.22M. The company also expects its adjusted EPS to be $0.55-$0.59, slightly lower than the estimated $0.59.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:34 pm

FREE

Whole Earth Brands (NASDAQ:FREE) reported Q3 GAAP EPS of $(0.13), missing the estimate of $(0.03) by 333.33%. The company also reported quarterly sales of $134.43M, missing the estimate of $141.78M by 5.18%. This represents a decrease in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:32 pm

BTTX

Better Therapeutics (NASDAQ:BTTX) reported its Q3 earnings, beating estimated earnings by 28.57% with an EPS of $-0.15 versus an estimate of $-0.21. However, revenue was down $0 from the same period last year. Last quarter, a beat on EPS was followed by a 1.62% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 12:30 pm

SLGL

Sol-Gel Technologies (NASDAQ:SLGL) reported Q3 earnings, beating estimated earnings by 8.7% with an EPS of $-0.21 versus an estimate of $-0.23. However, revenue was down $48 thousand from the same period last year. Last quarter, the company beat on EPS by $0.03, which was followed by a 9.66% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 12:30 pm

IPSC

Century Therapeutics (NASDAQ:IPSC) reported Q3 earnings, missing estimated earnings by 7.84% with an EPS of $-0.55 versus an estimate of $-0.51. Revenue was down $2.08 million from the same period last year. Last quarter, the company also missed on EPS by $0.02, which was followed by a 4.91% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 12:25 pm

DIS

QQQ

SPY

The stock market's momentum appears to be waning with futures suggesting a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co. posting encouraging quarterly results. Bond yields have started to rise in anticipation of the IMF panel discussion, featuring Federal Reserve Chair Jerome Powell. Morgan Stanley's Lisa Shalett remains wary of a potential slowing in economic growth, the specter of sticky inflation, the overall market trend remaining sideways and uninspiring, and the stresses emerging in the high-yield or speculative grade credit.

Portfolio Pulse from Shanthi Rexaline

November 09, 2023 | 12:25 pm

CABA

Cabaletta Bio (NASDAQ:CABA) reported its Q3 earnings, beating estimated earnings by 7.5% with an EPS of $-0.37 versus an estimate of $-0.4. However, revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.07, which was followed by an 11.0% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 12:25 pm

XTNT

Xtant Medical has increased its FY23 revenue guidance to $88M-$91M, up from the previous guidance of $75M-$77M and surpassing the consensus of $77.00M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:19 pm